Results 91 to 100 of about 7,490 (233)
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
Journal of Experimental Pharmacology, 2021 Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj
Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation [PDF]
, 2019 Background Accurate protein quantification is a vital prerequisite for generating meaningful predictions when using systems biology approaches, a method that is increasingly being used to unravel the complexities of sub cellular interactions and as part
Bye, Alexander P. +15 more
core +4 more sources
Polo‐like kinases and UV‐induced skin carcinogenesis: What we know and what's next
Photochemistry and Photobiology, EarlyView.The polo‐like kinase (PLK) family plays distinct and critical roles in the regulation of cell cycle progression, and its dysregulation has been implicated in various cancers. Ultraviolet (UV) radiation is a well‐established environmental factor in the development of skin cancer.
Tanya Jaiswal +3 more
wiley +1 more source
Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.
PLoS ONE, 2019 BackgroundPharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of ...
Sonja Hatz +9 more
doaj +1 more source
Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Frontiers in Immunology, 2017 Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
Alexander N. R. Weber +5 more
doaj +1 more source
International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg +5 more
wiley +1 more source
Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
eLife, 2015 Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang +6 more
doaj +1 more source
Targetable Vulnerabilities in MYC‐Driven B Cell Lymphomas Resistant to BCR Extinction
Hematological Oncology, Volume 44, Issue 2, March 2026.ABSTRACT Polatuzumab vedotin, an antibody‐drug conjugate (ADC) targeting the B cell receptor (BCR) signaling subunit CD79B, has recently entered frontline therapy for diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBCL), achieving encouraging clinical results. However, MYC‐driven B cell lymphomas, particularly HGBCL with MYC and
Silvia Brambillasca +15 more
wiley +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source